Physician profile

Katrina D Powers

Family Medicine · Independence, MO

NPI 1588622153

$1,302.52

in general payments reported to CMS, 2019-2025

26 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pfizer INC. $217.73 2019-2020
Merck Sharp & Dohme LLC $158.92 2019
Amgen INC. $149.44 2019
Astrazeneca Pharmaceuticals LP $122.69 2019-2020
Amarin Pharma, INC. $117.32 2019-2020
Allergan, INC. $62.07 2019
Shire North American Group INC $57.76 2019
Boehringer Ingelheim Pharmaceuticals, INC. $50.08 2019
Takeda Pharmaceuticals U.S.A., INC. $47.08 2019
Alimera Sciences, INC. $32.19 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $30.82 2019
Antares Pharma, INC. $29.06 2019-2020
Radius Health, INC. $24.43 2019
Kowa Pharmaceuticals America, INC. $23.76 2019
Philips North America LLC $20.17 2019
Show all 26 companies
CompanyGeneral paymentsYearsTop products
Bioventus LLC $18.15 2021
Janssen Pharmaceuticals, INC $16.23 2019
Astellas Pharma US INC $15.55 2019
Ibsa Pharma INC. $15.18 2019
Adlon Therapeutics L.P. $15.16 2019
Therapeuticsmd, INC. $15.07 2019
Assertio Therapeutics, INC. $13.69 2019
Nalpropion Pharmaceuticals LLC $13.58 2019
Lilly USA, LLC $13.26 2019
Arbor Pharmaceuticals, INC. $11.71 2019
Novo Nordisk INC $11.42 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Katrina D Powers

$1,302.52

in general payments reported 2019-2025

Years
2019-2021
Top company
Pfizer INC.

https://glasscript.com/doctor/207916/katrina-d-powers

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.